Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?

Detalles Bibliográficos
Autores principales: Mienko, Fiona, Halmos, Balazs, Cheng, Haiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333146/
https://www.ncbi.nlm.nih.gov/pubmed/32647703
http://dx.doi.org/10.21037/atm.2020.02.68
_version_ 1783553690198605824
author Mienko, Fiona
Halmos, Balazs
Cheng, Haiying
author_facet Mienko, Fiona
Halmos, Balazs
Cheng, Haiying
author_sort Mienko, Fiona
collection PubMed
description
format Online
Article
Text
id pubmed-7333146
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-73331462020-07-08 Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer? Mienko, Fiona Halmos, Balazs Cheng, Haiying Ann Transl Med Editorial Commentary AME Publishing Company 2020-06 /pmc/articles/PMC7333146/ /pubmed/32647703 http://dx.doi.org/10.21037/atm.2020.02.68 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
Mienko, Fiona
Halmos, Balazs
Cheng, Haiying
Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
title Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
title_full Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
title_fullStr Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
title_full_unstemmed Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
title_short Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
title_sort is pembrolizumab monotherapy the optimal treatment for elderly patients with pd-l1 positive advanced non-small cell lung cancer?
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333146/
https://www.ncbi.nlm.nih.gov/pubmed/32647703
http://dx.doi.org/10.21037/atm.2020.02.68
work_keys_str_mv AT mienkofiona ispembrolizumabmonotherapytheoptimaltreatmentforelderlypatientswithpdl1positiveadvancednonsmallcelllungcancer
AT halmosbalazs ispembrolizumabmonotherapytheoptimaltreatmentforelderlypatientswithpdl1positiveadvancednonsmallcelllungcancer
AT chenghaiying ispembrolizumabmonotherapytheoptimaltreatmentforelderlypatientswithpdl1positiveadvancednonsmallcelllungcancer

Ejemplares similares